The San Francisco Bay Area has experienced a particularly intense HIV epidemic, with men who have sex with men (MSM), Black, and Latino populations most heavily impacted in the region. Drs. Susan Buchbinder and Diane Havlir are scientific leaders in HIV prevention and treatment, respectively. Together they will form the San Francisco Bay Area Clinical Trials Unit (SFBay CTU), affiliated with the HVTN, HPTN, MTN, and ACTG. This integrated research organization will accomplish 3 specific aims through these Networks: 1) advance prevention and treatment science and their intersection through scientific leadership;2) implement clinical trials efficiently and with excellent adherence to protocol while engaging diverse communities;and 3) develop a new generation of diverse leaders in HIV prevention and treatment science. Drs. Buchbinder and Havlir are joined by a diverse pool of talented investigators who have provided leadership across the Networks, serving on numerous scientific leadership committees and working groups and chairing a range of prevention and treatment protocols. The 3 Clinical Research Sites (Bridge HIV led by Buchbinder, UCSF led by Havlir, and Stanford led by Zolopa) all have a record of excellence in enrollment, retention, and adherence to protocol requirements, and actively engage local communities in their research.

Public Health Relevance

The newly formed San Francisco Bay Clinical Trials Unit will conduct HIV vaccine, prevention and treatment trials in San Francisco, Oakland, San Jose, and their surrounding communities. By bringing together leading scientists and a diverse community in the San Francisco Bay Area, this new research unit will develop ways to prevent and treat HIV infections and work towards an effective HIV vaccine and cure.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069496-08
Application #
8610067
Study Section
Special Emphasis Panel (ZAI1-UKS-A (S1))
Program Officer
Jones, Patricia L
Project Start
2007-03-02
Project End
2020-11-30
Budget Start
2013-12-10
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$1,630,597
Indirect Cost
$90,474
Name
Public Health Foundation Enterprises
Department
Type
DUNS #
082199324
City
City of Industry
State
CA
Country
United States
Zip Code
91746
Cohen, Stephanie E; Vittinghoff, Eric; Bacon, Oliver et al. (2015) High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr 68:439-48
Bigira, Victor; Kapisi, James; Clark, Tamara D et al. (2014) Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 11:e1001689
Tenorio, Allan R; Zheng, Yu; Bosch, Ronald J et al. (2014) Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 210:1248-59
Sandler, Netanya G; Zhang, Xinyan; Bosch, Ronald J et al. (2014) Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 210:1549-54
Grinsztejn, Beatriz; Hosseinipour, Mina C; Ribaudo, Heather J et al. (2014) Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 14:281-90
Dooley, Kelly E; Luetkemeyer, Anne F; Park, Jeong-Gun et al. (2014) Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother 58:5245-52
Goepfert, Paul A; Elizaga, Marnie L; Seaton, Kelly et al. (2014) Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 210:99-110
Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J et al. (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161:461-71
Coombs, Angela; McFarland, Willi; Ick, Theresa et al. (2014) Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 66:e94-7
Kojic, Erna Milunka; Kang, Minhee; Cespedes, Michelle S et al. (2014) Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 59:127-35

Showing the most recent 10 out of 23 publications